Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-25-209537
Filing Date
2025-09-19
Accepted
2025-09-19 21:17:56
Documents
1
Period of Report
2025-09-19

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 6475
  Complete submission text file 0001193125-25-209537.txt   7896
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Issuer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O APELLIS PHARMACEUTICALS, INC. 6400 WESTWIND WAY, SUITE A CRESTWOOD KY 40014
Business Address
Dunlop A. Sinclair (Reporting) CIK: 0001721108 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38276 | Film No.: 251328264